Age-Related Macular Degeneration (AMD) Market: Trends, Challenges, and Future Opportunities

https://www.alliedmarketresearch.com/age-related-macular-degeneration-AMD-market

The age-related macular degeneration (AMD) market is experiencing significant growth, driven by the increasing aging population and advancements in treatment options. Valued at $9.4 billion in 2022, the market is projected to reach $15.4 billion by 2032, growing at a compound annual growth rate (CAGR) of 5% from 2023 to 2032. AMD, a leading cause of vision loss among the elderly, affects the macula, the central part of the retina responsible for sharp vision. This article explores the market trends, key drivers, and future opportunities in the AMD market.

Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/3538

Understanding Age-Related Macular Degeneration (AMD)
AMD is a progressive eye condition that primarily affects individuals over the age of 50. It is categorized into two types:
• Dry AMD: The more common form, characterized by the accumulation of drusen (yellow deposits) in the macula, leading to gradual vision loss.
• Wet AMD: Less common but more severe, involving the growth of abnormal blood vessels beneath the macula, which can leak fluid and cause rapid vision loss.
While dry AMD currently has no cure, treatments like vitamin supplements and lifestyle changes can slow its progression. Wet AMD is treated with anti-VEGF (vascular endothelial growth factor) therapies, which involve injecting medications into the eye to inhibit abnormal blood vessel growth.

Key Market Dynamics
1. Rising Geriatric Population
• By 2030, 1 in 6 people worldwide will be aged 60 or older.
• By 2050, the population aged 80 and above is expected to reach 426 million.
• This demographic shift is expected to significantly increase the prevalence of AMD, fueling demand for effective treatments.
2. Advancements in Treatment Options
• Anti-VEGF Therapies: Drugs like aflibercept and ranibizumab are widely used to treat wet AMD.
• Pipeline Drugs: Over 10 AMD drugs are in various stages of clinical trials, including ALK-001, Zimura, and OpRegen.
• Recent Approvals: In 2023, the FDA approved SYFOVRE (pegcetacoplan injection) for geographic atrophy, a severe form of dry AMD.
3. Increasing Awareness and Diagnosis
• Growing awareness and improved diagnostic techniques are enabling early detection and treatment.
• Government initiatives, such as India's National Programme for Control of Blindness and Visual Impairment (NPCB&VI), are promoting eye health and vision loss prevention.

Market Segmentation
By Drug Type
• Aflibercept: Dominates the market due to its effectiveness in treating wet AMD.
• Ranibizumab: A popular anti-VEGF therapy, available in biosimilar forms like Byooviz.
• Others: Includes emerging therapies and pipeline drugs.
By Disease Type
• Dry AMD: Accounts for most cases but lacks curative treatments.
• Wet AMD: Drives market revenue due to the high cost and efficacy of anti-VEGF therapies.
By Distribution Channels
• Hospital Pharmacies: Primary distribution channel for AMD drugs.
• Retail Pharmacies: Increasingly used for follow-up treatments.
• Online Pharmacies: Gaining traction due to convenience and accessibility.
By Region
• North America: Leads the market due to advanced healthcare infrastructure and strong presence of key players.
• Europe: Significant contributions from countries like Germany and the UK.
• Asia-Pacific: Expected to grow at the fastest rate, driven by investments and favorable government policies.
• LAMEA: Shows potential for growth, particularly in Brazil and South Africa.
Challenges and Opportunities

Challenges
• High Treatment Costs: The average cost of AMD treatment is $5,198.65 per person, limiting accessibility in low-income regions.
• Limited Insurance Coverage: Inadequate reimbursement policies in developing countries hinder market growth.
Opportunities
• Pipeline Drugs: Novel therapies for dry AMD present significant growth potential.
• Emerging Markets: Asia-Pacific and LAMEA regions offer untapped opportunities due to rising healthcare investments.
• Technological Innovations: Advances in gene therapy and sustained-release drug delivery systems are expected to revolutionize AMD treatment.
Competitive Landscape
The AMD market is highly competitive, with major players like Regeneron Pharmaceuticals, Novartis AG, Roche, and Bayer AG leading the way.

Key strategies include:
• Product Approvals: Roche's Susvimo (ranibizumab injection) received FDA approval in 2021.
• Collaborations: Partnerships between pharmaceutical companies and research institutions are accelerating drug development.
• Geographic Expansion: Companies are targeting emerging markets to capitalize on growing demand.
Future Outlook
The AMD market is poised for steady growth, driven by:
• The expanding geriatric population.
• Increasing prevalence of AMD worldwide.
• Ongoing research and development of innovative therapies.
By 2032, the market is expected to reach $15.4 billion, with Asia-Pacific emerging as a key growth region. Addressing challenges like high treatment costs and improving accessibility will be critical to unlocking the market's full potential.

Key Takeaways
• The AMD market is projected to grow at a CAGR of 5% from 2023 to 2032.
• Wet AMD dominates the market due to the efficacy of anti-VEGF therapies.
• North America leads the market, while Asia-Pacific is the fastest-growing region.
• Pipeline drugs and technological innovations offer significant growth opportunities.
• High treatment costs and limited insurance coverage remain key

challenges.
As the global population ages, the AMD market will continue to play a vital role in addressing vision loss and improving the quality of life for millions of elderly individuals worldwide.

Enquire Before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/3538

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int'l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
help@alliedmarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Allied Market Research is a top provider of market intelligence that offers reports from leading technology publishers. Our in-depth market assessments in our research reports take into account significant technological advancements in the sector. In addition to other areas of expertise, AMR focuses on the analysis of high-tech systems and advanced production systems. We have a team of experts who compile thorough research reports and actively advise leading businesses to enhance their current procedures. Our experts have a wealth of knowledge on the topics they cover. Also, they use a variety of tools and techniques when gathering and analyzing data, including patented data sources.

This release was published on openPR.